About E3 ubiquitin-protein ligase RNFT1
E3 ubiquitin-protein ligase RNFT1 (RNFT1) is a protein
from Homo sapiens identified by UniProt accession
Q5M7Z0, 435 residues long.
MolForge cross-references it against 0 known binders and
82 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RNFT1 |
| UniProt accession | Q5M7Z0 |
| Gene | RNFT1 |
| Organism | Homo sapiens |
| Length | 435 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (82)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- pulse pressure measurement · score 0.26
- Red cell distribution width · score 0.25
- erythrocyte count · score 0.20
- red blood cell density measurement · score 0.20
- monocyte count · score 0.19
- mean reticulocyte volume · score 0.15
- serum albumin measurement · score 0.15
- hematocrit · score 0.15
- bilirubin measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5M7Z0-F1 | alphafold | PREDICTED | 71.61 | — |
Amino-acid sequence (435 residues)
MPLFLLSLPT PPSASGHERR QRPEAKTSGS EKKYLRAMQA NRSQLHSPPG TGSSEDASTP QCVHTRLTGE GSCPHSGDVH IQINSIPKEC AENASSRNIR SGVHSCAHGC VHSRLRGHSH SEARLTDDTA AESGDHGSSS FSEFRYLFKW LQKSLPYILI LSVKLVMQHI TGISLGIGLL TTFMYANKSI VNQVFLRERS SKIQCAWLLV FLAGSSVLLY YTFHSQSLYY SLIFLNPTLD HLSFWEVFWI VGITDFILKF FFMGLKCLIL LVPSFIMPFK SKGYWYMLLE ELCQYYRTFV PIPVWFRYLI SYGEFGNVTR WSLGILLALL YLILKLLEFF GHLRTFRQVL RIFFTQPSYG VAASKRQCSD VDDICSICQA EFQKPILLIC QHIFCEECMT LWFNREKTCP LCRTVISDHI NKWKDGATSS HLQIY
Explore E3 ubiquitin-protein ligase RNFT1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets